Morgan Stanley’s upgrade of Synopsys (SNPS) to Overweight has pulled fresh attention to the stock after a pullback, with the firm highlighting Ansys integration prospects and AI driven demand in semiconductor design.
Synopsys shares trade at US$397.17 after a 1-day share price return of 1.0%. However, the 90-day share price return has declined 12.5% and the year-to-date share price return is down 17.3%, while the 5-year total shareholder return of 18.42% points to momentum that has cooled recently rather than steadily building.
Scan beyond Synopsys and see how other AI focused chip design players are setting up right now using our hand picked 89 AI infrastructure stocks
Synopsys now sits well below recent highs yet still carries a premium multiple and a bullish broker call. Does that mix still skew the risk reward toward buyers, or has the easy upside already been claimed?
Against Synopsys' last close at $397.17, the most widely followed valuation narrative pegs fair value higher, framing the recent pullback as a discount story rather than a momentum one.
The accelerating complexity and proliferation of AI, high-performance computing, and multi-die/chiplet-based architectures are increasing customer demand for Synopsys' advanced design, verification, and simulation solutions, solidifying its role as a mission-critical partner in next-generation chip and system development, supporting both revenue growth and opportunities for higher-margin recurring licensing.
Read the complete narrative. Read the complete narrative.
Want to see what is baked into that premium EDA view on Synopsys? The story focuses on compounding earnings, sturdier margins and a higher future profit multiple that assumes the market maintains strong demand for this kind of software. Curious which specific growth and profitability swing factors sit at the core of that fair value gap?
Result: Fair Value of $544.97 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, Synopsys faces real pressure points, with weaker China demand and higher integration and restructuring costs both capable of quickly challenging that undervalued narrative.
Find out about the key risks to this Synopsys narrative.
The DCF workup values Synopsys as 22.7% undervalued at $397.17, yet the P/E suggests a different picture. The stock trades around 70.7x earnings compared with about 29.5x for the wider US Software group and 31.1x for direct peers, while the fair ratio is closer to 45.5x. That gap points to notable valuation risk if sentiment cools, even if the cash flow model indicates potential upside. Which signal should serve as the anchor when the next headline hits?
See what the numbers say about this price — find out in our valuation breakdown.
If the mixed messages on Synopsys have you torn, act promptly and compare the potential upside with the concerns using the full breakdown of 3 key rewards and 2 important warning signs
Do not stop at Synopsys when there are plenty of other opportunities on the table. Use the tools available and let the data do the heavy lifting for you.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com